Plain-English translation of NCT07536802 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether adenosine, a medication that relaxes blood vessels and reduces inflammation, can improve outcomes when given before emergency heart surgery in people having a heart attack. Half of participants will receive adenosine before their procedure, and half will receive standard care alone. The study wants to see if the medication prevents a dangerous condition called 'no-reflow,' where blood doesn't reach heart tissue properly even after the blocked artery is opened.
After emergency heart surgery, some patients don't get adequate blood flow to their heart muscle even though the blocked artery is now open—a serious problem linked to worse outcomes. This trial exists to see whether giving this medication beforehand can prevent that dangerous complication.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will receive adenosine injected into the heart artery just before the emergency procedure; the other group will receive standard care alone. Your heart's blood flow will be carefully monitored during and after the procedure using standard imaging, and researchers will track your recovery and outcomes over the study period.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
Pakistan